San Diego-based Viking Therapeutics marked itself as a significant competitor during the weight loss drug market place in February following revealing promising facts from a mid-stage trial of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when offered as being a weekly injection and in March the com